RDP Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

RDP Pharma is a private, pre-clinical stage biotechnology company pioneering novel approaches to drug delivery and protein degradation. Its flagship technology, the PromptDegrader™ platform, is designed to rationally degrade disease-causing proteins with intrinsically disordered regions (IDRs), a class long considered undruggable. The company's pipeline includes programs targeting HPV-driven cancers (E7 Degrader), the MYC oncoprotein, and next-generation drug delivery modules, positioning it at the forefront of a challenging but high-potential therapeutic frontier. RDP is actively seeking development partners to advance its innovative portfolio.

OncologyInfectious Disease

Technology Platform

PromptDegrader™ (Protein Modulation Platform Technology) - a proprietary platform designed to identify and degrade disease-relevant proteins with intrinsically disordered regions (IDRs), a class historically considered 'undruggable'.

Opportunities

The company's platform targets the vast 'undruggable' proteome, specifically IDR proteins implicated in ~70% of cancers (like MYC) and other serious diseases, representing a multi-billion dollar market white space.

Successful validation of its E7 Degrader could address a clear unmet need in HPV-related cancers, providing a targeted therapeutic option.

The active search for partners indicates a pathway to non-dilutive funding and accelerated development through established industry players.

Risk Factors

The core scientific risk is extreme: proving effective degradation of dynamically disordered proteins in a living system is an unproven frontier with high technical failure risk.

As a private, pre-revenue company, it faces significant financial risk and dependency on securing partnerships to fund costly R&D.

The competitive landscape in protein degradation is intensifying, with larger, well-capitalized entities pursuing similar goals.

Competitive Landscape

RDP operates in the competitive field of targeted protein degradation, competing with public biotechs like Arvinas, Kymera Therapeutics, and Nurix Therapeutics, as well as large pharma internal efforts. Its specific niche focus on intrinsically disordered proteins (IDRs) may offer differentiation, but it faces competition from other modalities (e.g., molecular glues, PPI inhibitors) also aiming to drug these targets. Success will depend on demonstrating superior platform efficacy and specificity.

More companies in Drug Delivery & Formulation →More companies in Switzerland →